Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhongzhi Pharmaceutical Holdings's EV-to-FCF or its related term are showing as below:
HKSE:03737'
s EV-to-FCF Range Over the Past 10 Years
Min: -360.91 Med: -3.89 Max: 228.17
Current: 4.1
During the past 12 years, the highest EV-to-FCF of Zhongzhi Pharmaceutical Holdings was 228.17. The lowest was -360.91. And the median was -3.89.
HKSE:03737's EV-to-FCF is ranked better than 92.58% of 566
companies
in the Drug Manufacturers industry
Industry Median: 19.82
vs HKSE:03737: 4.10
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhongzhi Pharmaceutical Holdings's PE Ratio (TTM) for today is calculated as:
Zhongzhi Pharmaceutical Holdings's share price for today is HK$0.71.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zhongzhi Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhongzhi Pharmaceutical Holdings EV-to-FCF Related Terms
Zhongzhi Pharmaceutical Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhongzhi Pharmaceutical Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongzhi Pharmaceutical Holdings EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhongzhi Pharmaceutical Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zhongzhi Pharmaceutical Holdings's EV-to-FCF falls into.
Zhongzhi Pharmaceutical Holdings's current Enterprise Value is HK$666 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zhongzhi Pharmaceutical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$158 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongzhi Pharmaceutical Holdings (HKSE:03737) has a EV-to-FCF of 4.20 as of Sep. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhongzhi Pharmaceutical Holdings and its competitors. According to the industry distribution chart, Zhongzhi Pharmaceutical Holdings ranks #42 out of 566 companies in the Drug Manufacturers industry, placing it in the top 7.4%.
Is Zhongzhi Pharmaceutical Holdings' EV-to-FCF too high?
Zhongzhi Pharmaceutical Holdings' current EV-to-FCF is 4.20. The Drug Manufacturers industry median EV-to-FCF is 19.82. Zhongzhi Pharmaceutical Holdings' value of 4.20 is 78.8% below this industry median. Based on the distribution chart, Zhongzhi Pharmaceutical Holdings ranks #42 out of 566 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhongzhi Pharmaceutical Holdings has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongzhi Pharmaceutical Holdings' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhongzhi Pharmaceutical Holdings ranks #42 out of 566 companies for EV-to-FCF. This places Zhongzhi Pharmaceutical Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 19.82. Zhongzhi Pharmaceutical Holdings' value of 4.20 is 78.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.82, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhongzhi Pharmaceutical Holdings's current EV-to-FCF of 4.20 is 78.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhongzhi Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhongzhi Pharmaceutical Holdings's current EV-to-FCF is 4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongzhi Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zhongzhi Pharmaceutical Holdings (HKSE:03737) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.89, compared to a current price of HK$0.71 — trading 20.2% below its estimated fair value. The current EV-to-FCF is 4.20 and 78.8% below the Drug Manufacturers industry median of 19.82. Zhongzhi Pharmaceutical Holdings' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhongzhi Pharmaceutical Holdings (HKSE:03737), the current EV-to-FCF is 4.20 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongzhi Pharmaceutical Holdings (HKSE:03737) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongzhi Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of HK$0.71 is trading 20.2% below its estimated GF Value™ of HK$0.89.
GuruFocus considers Zhongzhi Pharmaceutical Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:03737:
EV-to-FCF: 4.20
GF Value™: HK$0.89 vs. price of HK$0.71 (20.2% below fair value)
Industry Position: 78.8% below the Drug Manufacturers median (#42 of 566)
No single metric tells the full story. See the HKSE:03737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongzhi Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceutical products in the PRC. The Group is a large industrial and trading enterprise group featuring researching, producing, and selling traditional Chinese medicine preparations, prepared slices of Chinese crude drugs, and foods. Its products include Shenqi Koufuye, Yinhuang Jiaonang, Yinhuang Keli, and others. Its segments are the pharmaceutical manufacturing segment, which generates maximum revenue, is engaged in the research and development, manufacturing, and sale of Chinese patent medicines and decoction pieces consisting of traditional decoction pieces and modern decoction pieces, and the operation of the chain pharmacies segment.
47GF Score
Get the complete analysis for HKSE:03737
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03737 has been successfully added to your 
